• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medecine Nucleaire >Radionuclide therapy targeting PSMA for the treatment of metastatic prostate cancer: Current point of view and ways of improvement
【24h】

Radionuclide therapy targeting PSMA for the treatment of metastatic prostate cancer: Current point of view and ways of improvement

机译：靶向PSMA的放射性核素治疗转移性前列腺癌的治疗：当前观点和改善方法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metastatic castration-resistant prostate cancer (mCRPC) still represents a challenge and an unmet clinical need. RadioLigand therapy targeting PSMA (PRLT) has been used for several years with success and low toxicity. The first radionuclide used were radiolabeled antibody with limited dose due to hematologic toxicity. Rapidly, small molecules targeting PSMA were developed and used with lower toxicity, mostly related to mild transient xerostomia and nausea due to physiological PSMA expression in the salivary glands and proximal bowel. Briefly, 2/3 of the patients may first respond to treatments followed by disease recurrence responding to further cycles for half of them. Therefore, there is a need to improve again the PRLT efficacy and the ways of improvement will be discussed in this review. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译：转移性去势抵抗性前列腺癌（mCRPC）仍然是一项挑战，也是一项尚未满足的临床需求。针对PSMA（PRLT）的RadioLigand治疗已经成功使用了几年并且毒性低。由于血液学毒性，使用的第一种放射性核素是剂量受限的放射性标记抗体。很快，针对PSMA的小分子被开发出来并以较低的毒性使用，这主要与唾液腺和近端肠中生理性PSMA的表达引起的轻度短暂口干症和恶心有关。简而言之，2/3的患者可能首先对治疗有反应，然后对一半患者的进一步周期产生疾病复发。因此，有必要再次提高PRLT的功效，本次审查将讨论改善方式。 （C）2019 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号